{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:10:07Z","timestamp":1721607007197},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1684\/bdc.2014.1886","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T20:02:13Z","timestamp":1565726533000},"page":"211-218","source":"Crossref","is-referenced-by-count":0,"title":["Int\u00e9r\u00eat du gemtuzumab ozogamicin dans les leuc\u00e9mies aigu\u00ebs my\u00e9lo\u00efdes"],"prefix":"10.1016","volume":"101","author":[{"given":"Thibault","family":"Brotelle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Lemal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Molu\u00e7on-Chabrot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques-Olivier","family":"Bay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Delaunay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"Gui\u00e8ze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1684\/bdc.2014.1886_bib0005","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10637-012-9877-8","article-title":"Differences in drug approval processes of 3 regulatory agencies: a case study of gemtuzumab ozogamicin","volume":"31","author":"Tanimoto","year":"2013","journal-title":"Invest New Drugs"},{"key":"10.1684\/bdc.2014.1886_bib0010","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1182\/blood.V67.4.1048.1048","article-title":"Expression of normal myeloid-associated antigens by acute leukemia cells","volume":"67","author":"Dinndorf","year":"1986","journal-title":"Blood"},{"key":"10.1684\/bdc.2014.1886_bib0015","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1084\/jem.169.5.1721","article-title":"Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties","volume":"169","author":"Andrews","year":"1989","journal-title":"J Exp Med"},{"key":"10.1684\/bdc.2014.1886_bib0020","first-page":"3336","article-title":"Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics","volume":"53","author":"Hinman","year":"1993","journal-title":"Cancer Res"},{"key":"10.1684\/bdc.2014.1886_bib0025","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.1073\/pnas.091097198","article-title":"Surface expression and function of p75\/AIRM-1 or CD33 in acute myeloid leukemias: engagement of CD33 induces apoptosis of leukemic cells","volume":"98","author":"Vitale","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1684\/bdc.2014.1886_bib0030","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1182\/blood.V97.10.3197","article-title":"Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells","volume":"97","author":"van der Velden","year":"2001","journal-title":"Blood"},{"key":"10.1684\/bdc.2014.1886_bib0035","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1182\/blood.V98.4.988","article-title":"Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin","volume":"98","author":"Linenberger","year":"2001","journal-title":"Blood"},{"key":"10.1684\/bdc.2014.1886_bib0040","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1182\/blood-2003-02-0396","article-title":"Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells","volume":"102","author":"Walter","year":"2003","journal-title":"Blood"},{"key":"10.1684\/bdc.2014.1886_bib0045","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1182\/blood.V93.11.3678","article-title":"Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate","volume":"93","author":"Sievers","year":"1999","journal-title":"Blood"},{"key":"10.1684\/bdc.2014.1886_bib0050","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","article-title":"Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse","volume":"19","author":"Sievers","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2014.1886_bib0055","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1038\/sj.leu.2402677","article-title":"Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)","volume":"16","author":"Larson","year":"2002","journal-title":"Leukemia"},{"key":"10.1684\/bdc.2014.1886_bib0060","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/cncr.21326","article-title":"Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence","volume":"104","author":"Larson","year":"2005","journal-title":"Cancer"},{"key":"10.1684\/bdc.2014.1886_bib0065","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.leukres.2006.07.005","article-title":"Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project","volume":"31","author":"McKoy","year":"2007","journal-title":"Leuk Res"},{"key":"10.1684\/bdc.2014.1886_bib0070","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/bmt.2009.153","article-title":"Prior treatment with gemtuzumab ozogamicin and the risk of veno-occlusive disease after allogeneic haematopoietic stem cell transplantation","volume":"45","author":"Chevallier","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1684\/bdc.2014.1886_bib0075","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1182\/blood.V99.7.2310","article-title":"Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy","volume":"99","author":"Rajvanshi","year":"2002","journal-title":"Blood"},{"key":"10.1684\/bdc.2014.1886_bib0080","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/sj.leu.2404434","article-title":"High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group","volume":"21","author":"Taksin","year":"2007","journal-title":"Leukemia"},{"key":"10.1684\/bdc.2014.1886_bib0085","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.leukres.2004.04.011","article-title":"Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older","volume":"29","author":"Nabhan","year":"2005","journal-title":"Leuk Res"},{"key":"10.1684\/bdc.2014.1886_bib0090","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1038\/sj.leu.2403901","volume":"19","author":"Amadori","year":"2005","journal-title":"Leukemia"},{"key":"10.1684\/bdc.2014.1886_bib0095","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1365-2141.2010.08095.x","volume":"149","author":"Amadori","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1684\/bdc.2014.1886_bib0100","doi-asserted-by":"crossref","first-page":"5192","DOI":"10.1200\/JCO.2007.15.9764","article-title":"Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia","volume":"26","author":"Chevallier","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2014.1886_bib0105","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.leukres.2010.07.017","article-title":"High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902","volume":"35","author":"Stone","year":"2011","journal-title":"Leuk Res"},{"key":"10.1684\/bdc.2014.1886_bib0110","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1182\/blood-2003-05-1620","article-title":"A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia","volume":"102","author":"Kell","year":"2003","journal-title":"Blood"},{"key":"10.1684\/bdc.2014.1886_bib0115","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","article-title":"A phase III study of gemtuzumab ozogamicin during induction and post-consolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"key":"10.1684\/bdc.2014.1886_bib0120","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","article-title":"Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial","volume":"29","author":"Burnett","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2014.1886_bib0125","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1200\/JCO.2012.42.2964","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia","volume":"30","author":"Burnett","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2014.1886_bib0130","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"key":"10.1684\/bdc.2014.1886_bib0135","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/sj.leu.2403350","article-title":"High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients","volume":"18","author":"van der Velden","year":"2004","journal-title":"Leukemia"},{"key":"10.1684\/bdc.2014.1886_bib0140","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/sj.leu.2403598","article-title":"CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug-resistance","volume":"19","author":"Linenberger","year":"2005","journal-title":"Leukemia"},{"key":"10.1684\/bdc.2014.1886_bib0145","first-page":"79","article-title":"Addition of Gemtuzumab Ozogamycin to Chemotherapy Improves Event-Free Survival but Not Overall Survival of AML Patients with Intermediate Cytogenetics Not Eligible for Allogeneic Transplantation. Results of the GOELAMS AML 2006 IR Study","volume":"118","author":"Delaunay","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1684\/bdc.2014.1886_bib0150","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/leu.2012.229","article-title":"The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison","volume":"27","author":"Burnett","year":"2013","journal-title":"Leukemia"},{"key":"10.1684\/bdc.2014.1886_bib0155","first-page":"950","article-title":"Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups","volume":"89","author":"Amadori","year":"2004","journal-title":"Haematologica"},{"key":"10.1684\/bdc.2014.1886_bib0160","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","article-title":"Anthracycline dose intensification in acute myeloid leukemia","volume":"361","author":"Fernandez","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2014.1886_bib0165","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1365-2141.2010.08168.x","article-title":"Low-dose Gemtuzumab-Ozogamicin as post-consolidation therapy in elderly patients with acute myeloid leukaemia: a pilot study","volume":"150","author":"Poloni","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1684\/bdc.2014.1886_bib0170","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2009-10-246470","article-title":"Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study","volume":"115","author":"L\u00f6wenberg","year":"2010","journal-title":"Blood"},{"key":"10.1684\/bdc.2014.1886_bib0175","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1365-2141.1998.00871.x","article-title":"Immunophenotype of adult and childhood acute promyelocytic leukemia: correlation with morphology and type of PML gene breakpoint: a cooperative Italian study on 196 cases","volume":"102","author":"Guglielmi","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1684\/bdc.2014.1886_bib0180","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1182\/blood-2004-04-1550","article-title":"Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia","volume":"104","author":"Lo-Coco","year":"2004","journal-title":"Blood"},{"key":"10.1684\/bdc.2014.1886_bib0185","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1182\/blood-2001-12-0174","article-title":"Experience with gemtuzumab ozogamycin (\u201cmylotarg\u201d) and all-trans retinoic acid in untreated acute promyelocytic leukemia","volume":"99","author":"Estey","year":"2002","journal-title":"Blood"},{"key":"10.1684\/bdc.2014.1886_bib0190","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1200\/JCO.2007.13.0096","article-title":"Safety and Efficacy of Gemtuzumab Ozogamicin in Combination With Chemotherapy for Pediatric Acute Myeloid Leukemia: A Report From The Children's Oncology Group","volume":"26","author":"Aplenc","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2014.1886_bib0195","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/cncr.26190","article-title":"AAML03P1, a Pilot Study of the Safety of Gemtuzumab Ozogamicin in Combination With Chemotherapy for Newly Diagnosed Childhood Acute Myeloid Leukemia: a report from the Children's Oncology Group","volume":"118","author":"Cooper","year":"2012","journal-title":"Cancer"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115301405?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115301405?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T23:57:07Z","timestamp":1721606227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455115301405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0007455115301405"],"URL":"https:\/\/doi.org\/10.1684\/bdc.2014.1886","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}